Aurora Cannabis, Canopy Growth, Cronos Group, and Aphria Inc., struck a big win this week as a new study has been released that shows Cannabis with THC has shown to not only provide levels of pain relief for fibromyalgia pain, but has now conclusively shown to increase communication and functionality in children with Autism.
The Autistic community has long advocated the effectiveness of Cannabis, however studies backing their claims were limited. This was mainly due to the red tape surrounding Cannabis, especially when it came to administering to children. Now the Autistic community has real-world studies to confirm their beliefs in the therapeutic effectiveness of Cannabis.
A recent study out of Israel revealed new evidence to back up the claims that Cannabis is a superior treatment options for Autism. Published Jan 17. in the journal Nature, the study found that cannabis can relieve the symptoms suffered by many autistic people, including seizures, restlessness, and rage attacks.
188 autism spectrum disorder (ASD) patients over a six-month period. The subjects were mostly male (81.9%) and had a mean age of 12.9 years, with 14 of the participants younger than five, 70 patients between six and 10, and 72 patients between 11 and 18.
This is the first major study to be published in a high profile scientific Journal that proves the therapeutic effectiveness in treating Autism.
“Cannabis in ASD patients appears to be well tolerated, safe and effective option to relieve symptoms associated with ASD.”
From this, many analysts are suggesting that the marijuana and hemp powerhouses are posturing to push forward with a major move into the US markets, and also planning on finally trademarking their Cannabis products now that the DEA and FDA have opened the door to US Cannabis Trademark Patents.
What about Federal Trademarks?
Federal trademarks have made their way throughout the medical community, But what about CBD? If CBD products are “legal under federal law,” why can’t they obtain federal trademark protection? Part of the issue that remains, even in light of the legalization of industrial hemp, is that the FDA still says that CBD cannot be sold for human consumption unless it has undergone the agency’s drug approval process. Currently, Epidiolex is the only FDA-approved CBD-based drug, which was rescheduled to Schedule V of the Controlled Substances Act (CSA) in September. This will allow for Aphria, Cronos, Canopy Growth, and Aurora to significantly expand, and look into more intellectual property to protect, within the USA.
One emerging Cannabis company has tailored some products to senior citizens with their line of calming and therapeutic soaps. Profile Solutions Inc (OTC:PSIQ)instead has purchased one of the most well known brands in the Cannabis industry, that of Cheech & Chong Product Line. While these are currently only mens grooming products, they are already trade marked. Now, when their large scale growing operation goes operational (See Here), they will only have to put the CBD products under the banner of Cheech and Chong, and thus it would be trade marked.
Aphria, Cronos, Canopy Growth and Aurora All have shared interested in expanding into the US Markets, opening up US Patents on Cannabis products.
The first obvious step would be to be granted an import license, which simply signifies cooperation from the DEA. To date, Tilray Inc. was one of the first received approval cases from the Drug Enforcement Administration to import cannabis into the U.S. for medical research, the first Canadian company to do so. Tilray will work with the University of California San Diego’s Center for Medicinal Cannabis Research on a clinical trial to test whether the drug can effectively treat essential tremor, a common neurological disorder that causes uncontrollable shaking and affects more than 4 percent of people over age 65.
Aphria has already signified patent and trademark intentions, along with their desire to enter more US markets, they will surely be pushing for some trademarked (SR1) patents.